Hosted on MSN
Roche says experimental drug helped slow disability in progressive multiple sclerosis study
Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is an ...
Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders through chronic inflammation. However, its role in multiple sclerosis, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results